髓系肉瘤合并嗜酸性粒细胞增多症、多发性骨髓瘤1例 - 百度开云体育app

国际肿瘤学杂志››2025,Vol. 52››Issue (5): 331-333.doi:10.3760/cma.j.cn371439-20240716-00056

• 病例报道 •上一篇下一篇

髓系肉瘤合并嗜酸性粒细胞增多症、多发性骨髓瘤1例

孔雪源, 王国田, 龙欣欣, 周茜茜, 李苓()

山东省滕州市中心人民医院肿瘤三科，滕州 277500

收稿日期:2024-07-16修回日期:2025-04-03出版日期:2025-05-08发布日期:2025-06-24
通讯作者:李苓 E-mail:lilingtz@163.com

Received:2024-07-16Revised:2025-04-03Online:2025-05-08Published:2025-06-24

摘要/Abstract

摘要：

髓系肉瘤是一种髓系不成熟细胞在髓外组织浸润形成的实体恶性肿瘤，可合并存在第二种血液学疾病，临床症状缺乏特异性，具有较高的误诊率，现报道1例髓系肉瘤合并嗜酸性粒细胞增多症、多发性骨髓瘤的患者，并复习相关文献，以提高对该病的认识。

孔雪源, 王国田, 龙欣欣, 周茜茜, 李苓. 髓系肉瘤合并嗜酸性粒细胞增多症、多发性骨髓瘤1例[J]. 国际肿瘤学杂志, 2025, 52(5): 331-333.

图/表3

参考文献19

[1]	Shallis RM, Gale RP, Lazarus HM, et al. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: a tale of misnomers, controversy and the unresolved[J].Blood Rev,2021,47: 100773. DOI:10.1016/j.blre.2020.100773.
[2]	Marra A, Martino G. Placental myeloid sarcoma[J].Blood,2020,135(16): 1410. DOI:10.1182/blood.2020004975.
[3]	El Hussein S, Hu S, Fang H, et al. Well-differentiated systemic astocytosis with associated myeloid sarcoma and myelodysplastic syndrome: diagnostic challenges of an underrecognized entity[J].Leuk Lymphoma,2022,63(1): 235-238. DOI:10.1080/10428194. 2021.1978089.
[4]	Rizzuto G, Leoncin M, Imbergamo S, et al. Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1-JAK2 positive myeloid sarcoma and acute B-lymphoblastic leukemia[J].Clin Case Rep,2022,10(1): e05212. DOI:10.1002/ccr3.5212.
[5]	Matrai Z, Andrikovics H, Csomor J, et al. Extramedullary myeloid sarcoma with eosinophilia and FIP1L1-PDGFRA rearrangement: complete cytogenetic response to imatinib therapy[J].Blood,2013,122(21): 5033. DOI:10.1182/blood.V122.21.5033.5033.
[6]	Chen D, Bachanova V, Ketterling RP, et al. A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease[J].Am J Surg Pathol,2013,37(1): 147-151. DOI:10.1097/PAS.0b013e31826df00b. pmid:23232855
[7]	Claerhout H, Van Aelst S, Melis C, et al. Clinicopathological characte-ristics of de novo and secondary myeloid sarcoma: a monocentric retrospective study[J].Eur J Haematol,2018,100(6): 603-612. DOI:10.1111/ejh.13056. pmid:29532520
[8]	Kaur V, Swami A, Alapat D, et al. Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years[J].Hematology,2018,23(1): 17-24. DOI:10.1080/10245332.2017.1333275. pmid:28574302
[9]	范憬超, 游伟文, 刘焕勋, 等. 伊马替尼治疗FIP1L1-PDGFRA融合基因阳性伴嗜酸性粒细胞增多的急性髓系白血病一例报告并文献复习[J].中华血液学杂志,2020,41(12): 1044-1046. DOI:10.3760/cma.j.issn.0253-2727.2020.12.014.
[10]	Werstein B, Dunlap J, Cascio MJ, et al. Molecular discordance between myeloid sarcomas and concurrent bone marrows occurs in actionable genes and is associated with worse overall survival[J].J Mol Diagn,2020,22(3): 338-345. DOI:10.1016/j.jmoldx.2019. 11.004. pmid:31866570
[11]	Greenland NY, Van Ziffle JA, Liu YC, et al. Genomic analysis in myeloid sarcoma and comparison with paired acute myeloid leukemia[J].Hum Pathol,2021,108: 76-83. DOI:10.1016/j.humpath.2020. 11.005. pmid:33232718
[12]	冷芸, 王慧娟, 周慧星, 等. 多发性骨髓瘤伴发第二肿瘤与恶性肿瘤伴发多发性骨髓瘤的临床特征分析[J].中华医学杂志,2022,102(32): 2523-2529. DOI:10.3760/cma.j.cn112137-20220118-00126.
[13]	Musto P, Anderson KC, Attal M, et al. Second primary malignancies in multiple myeloma: an overview and IMWG consensus[J].Ann Oncol,2017,28(2): 228-245. DOI:10.1093/annonc/mdw606. pmid:27864218
[14]	Ando T, Mitani N, Matsunaga K, et al. Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation[J].Tohoku J Exp Med,2010,220(2): 121-126. DOI:10.1620/tjem.220.121. pmid:20139663
[15]	孙琦, 李文倩, 解友邦, 等. 化疗后骨髓抑制机制的研究进展[J].国际肿瘤学杂志,2023,50(1): 33-36. DOI:10.3760/cma.j.cn371439-20221005-00006.
[16]	Ovilla-Martinez R, Weber Sánchez LA, Cota-Rangel X, et al. Gemtuzumab-ozogamicin and blinatumomab as treatment for refractory mixed-phenotype blast crisis in chronic myeloid leukaemia[J].BMJ Case Rep,2021,14(11): e243745. DOI:10.1136/bcr-2021-243745.
[17]	杨鹏, 陈小丽, 冯娜, 等. 纵隔原发性粒细胞肉瘤二例[J].中华肺部疾病杂志(电子版),2020,13(3): 414-416. DOI:10.3877/cma.j.issn.1674-6902.2020.03.030.
[18]	Ganzel C, Manola J, Douer D, et al. Extramedullary disease in adult acute myeloid leukemia is common but lacks independent significance: analysis of patients in ECOG-ACRIN cancer research group trials, 1980-2008[J].J Clin Oncol,2016,34(29): 3544-3553. DOI:10.1200/JCO.2016.67.5892. pmid:27573652
[19]	Eckardt JN, Stölzel F, Kunadt D, et al. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations[J].J Hematol Oncol,2022,15(1): 60. DOI:10.1186/s13045-022-01267-7.

相关文章15

编辑推荐

Metrics

本文评价